This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $766,877 randomized controlled trial to evaluate the efficacy of therapeutic drug monitoring (TDM) for linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The primary objective is to determine if TDM can prevent premature discontinuation of linezolid, a critical drug for treating RR-TB. The...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is supporting the development of a clinical decision support tool to optimize antibiotic selection for patients with rifampicin-resistant tuberculosis (RR-TB). The total funding amount is $647,922.00, with an award date of Jul 18, 2024 and an ultimate completion date of Jun 30, 2029. The project aims to create a tool that...
This Cooperative Agreement award, funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), supports a two-phase project to develop and test a biomarker-guided approach for selecting the most effective antidepressant treatment for individuals with treatment-resistant depression (TRD). The total funding amount is $2,754,722, with a project period from September 15, 2024 to September 14, 2026. In the initial UG3 phase, the project...
This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to develop a decision support tool for early introduction of clozapine treatment in first-episode psychosis (FEP) patients. The $779,842 award, effective September 5, 2024 through July 31, 2029, will fund a multi-center, randomized clinical trial to evaluate the efficacy of using biomarkers (functional brain scan, genetic tests for weight gain and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $811,443.00 to Beth Israel Deaconess Medical Center, Inc. to conduct a cluster randomized trial evaluating the impact of a shared decision-making training program for breast surgeons and a decision aid for women aged 70+ newly diagnosed with early-stage, low-risk breast cancer. The goal is to assess whether this intervention reduces the use of low-value treatments, such as mastectomy, sentinel...
This Project Grant award from the National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) will provide $311,999 to the University of Texas Health Science Center at Houston (UTHealth) to analyze datasets and develop a framework for identifying chronotherapeutic targets against pancreatic ductal adenocarcinoma (PDA). The objectives are to: 1) Profile the cancer-specific molecular rhythmicity of human pancreatic tissue, including tumor and tumor-infiltrating immune cells, using...
The Regional Health Systems (RHS) was awarded a $2,250,000 Project Grant from the Substance Abuse and Mental Health Services Administration (SAMHSA) under the Assisted Outpatient Treatment (AOT) Program (CFDA 93.997). The purpose of this four-year grant is to develop an AOT program for individuals with serious mental illness (SMI) and/or co-occurring disorders who are under outpatient civil commitment in Indiana. RHS will utilize the Forensic Assertive Community Treatment (FACT) and Adult...
The Bureau of Justice Assistance (BJA) has awarded a $1,000,000 Project Grant under the Treatment Court Discretionary Grant Program (CFDA 16.585) to My Health My Resources of Tarrant County (MHMR), a local government entity in Texas. The grant will fund the enhancement and improvement of the Tarrant County Adult Drug Court (Direct to Recovery, or DTR) program through the implementation of Moral Reconation Therapy (MRT). The project aims to reduce substance use and recidivism among high-risk...
The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...
This Project Grant award from the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program will fund a two-phased project to examine the feasibility, effectiveness, and implementation of a remote therapeutic monitoring (RTM) solution to enhance physical therapy outcomes for patients with musculoskeletal pain. During the initial R21 phase, the project will assess the feasibility of implementing RTM among a pilot group...